AlphaQuest LLC Cuts Stock Holdings in DaVita Inc. (NYSE:DVA)

AlphaQuest LLC cut its stake in DaVita Inc. (NYSE:DVA) by 40.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,413 shares of the company’s stock after selling 1,668 shares during the period. AlphaQuest LLC’s holdings in DaVita were worth $361,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of DVA. Amundi grew its position in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after buying an additional 240,126 shares in the last quarter. FMR LLC lifted its stake in DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after acquiring an additional 154,061 shares during the last quarter. Glenmede Trust Co. NA grew its holdings in DaVita by 731.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after acquiring an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Finally, KBC Group NV lifted its position in shares of DaVita by 27.3% during the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after purchasing an additional 67,250 shares during the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Up 1.7 %

NYSE:DVA opened at $143.56 on Friday. The company has a market capitalization of $11.48 billion, a PE ratio of 13.37, a P/E/G ratio of 1.07 and a beta of 0.99. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60. The stock’s 50 day moving average price is $158.92 and its 200 day moving average price is $157.60. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on DVA. Barclays increased their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, DaVita presently has an average rating of “Hold” and a consensus price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.